University of Pennsylvania

Novartis Ag

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The Children's Hospital of Philadelphia

USA As Represented by Secretary of the Navy

The Trustees of the University of Pennyslvania

Bruce L Levine

Carl H June

Michael C Milone

Michael D Kalos

David L Porter

James L Riley

Daniel J Powell

Jan J Melenhorst

Anne Chew

Richard G Carroll

Felipe Bedoya

Saba Ghassemi

Zoe Zheng

Stephen J Schuster

Bruce Robert Blazar

Wayne R Godfrey

Patricia Taylor

Chrystal Paulos

Daniel H Fowler

Stephan Grupp

Ronald E Gress

Omkar U Kawalekar

Unsu Jung

Daniel C St Louis

Nathan Amar Singh

David M Barrett

David Maxwell Barrett

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Methods for improving the efficacy and expansion of immune cells

Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells

The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.

Methods for treating chronic lymphocytic leukemia (CLL)

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CART cell in the patient.

Toxicity management for anti-tumor activity of CARs

The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.

ICOS critically regulates the expansion and function of inflammatory human Th17 cells

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.

Methods of making chimeric antigen receptor-expressing cells

The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject.

Methods for assessing the suitability of transduced T cells for administration

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

Compositions and methods for treatment of cancer

Use of chimeric antigen receptor-modified T-cells to treat cancer

Growing community of inventors

Cherry Hill, NJ, United States of America

Bruce L Levine